Published in Int J Cancer on August 01, 2008
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene (2012) 3.83
Epigenetic resensitization to platinum in ovarian cancer. Cancer Res (2012) 1.88
Minireview: epigenetic changes in ovarian cancer. Endocrinology (2009) 1.49
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer (2010) 1.34
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol (2009) 1.26
Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol (2010) 1.20
DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics (2012) 1.07
Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist (2012) 1.04
Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br J Cancer (2012) 1.01
HOX genes in ovarian cancer. J Ovarian Res (2011) 0.99
Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. Epigenetics (2013) 0.96
The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res (2014) 0.92
Epigenomics and ovarian carcinoma. Biomark Med (2010) 0.91
Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression. PLoS One (2013) 0.90
Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma. World J Gastroenterol (2011) 0.88
Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget (2014) 0.88
The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer. Oncotarget (2016) 0.84
Expression of HOXA11 in the mid-luteal endometrium from women with endometriosis-associated infertility. Reprod Biol Endocrinol (2012) 0.82
HOXA11 hypermethylation is associated with progression of non-small cell lung cancer. Oncotarget (2013) 0.82
Asparagine synthetase: a new potential biomarker in ovarian cancer. Drug News Perspect (2009) 0.82
Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma. Cancer Res Treat (2016) 0.81
Microarray-based DNA methylation study of Ewing's sarcoma of the bone. Oncol Lett (2014) 0.80
DNA methylation changes in epithelial ovarian cancer histotypes. Genomics (2015) 0.80
Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation. Epigenetics (2014) 0.80
A gene expression profile test for the differential diagnosis of ovarian versus endometrial cancers. Oncotarget (2012) 0.79
HOXA10 controls proliferation, migration and invasion in oral squamous cell carcinoma. Int J Clin Exp Pathol (2015) 0.78
Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice. J Cancer (2016) 0.78
The function of homeobox genes and lncRNAs in cancer. Oncol Lett (2016) 0.78
HOXA11 gene is hypermethylation and aberrant expression in gastric cancer. Cancer Cell Int (2014) 0.78
Ovarian stem cells: From basic to clinical applications. World J Stem Cells (2015) 0.77
DNA methylation, histone modifications, and signal transduction pathways: a close relationship in malignant gliomas pathophysiology. J Signal Transduct (2012) 0.76
Epigenetic inactivation of HOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification. Oncotarget (2017) 0.75
Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer. Oncotarget (2016) 0.75
Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer. Oncol Lett (2016) 0.75
Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. Br J Cancer (2017) 0.75
Clinical Significance and Effect of lncRNA HOXA11-AS in NSCLC: A Study Based on Bioinformatics, In Vitro and in Vivo Verification. Sci Rep (2017) 0.75
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics (2012) 4.95
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One (2009) 3.33
Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol (2005) 3.15
Independent surrogate variable analysis to deconvolve confounding factors in large-scale microarray profiling studies. Bioinformatics (2011) 2.91
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol (2003) 2.58
CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol (2006) 2.47
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res (2003) 2.14
Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology (2014) 2.02
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol (2012) 1.90
The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol (2013) 1.83
Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet (2004) 1.80
Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One (2008) 1.75
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. Methods (2010) 1.71
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med (2012) 1.65
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62
Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 1.59
DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther (2004) 1.53
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med (2012) 1.53
Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics (2012) 1.51
Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res (2004) 1.45
Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history. J Clin Virol (2004) 1.45
Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG (2014) 1.43
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum Mol Genet (2009) 1.42
Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol (2003) 1.39
Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep (2007) 1.34
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet (2012) 1.33
Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. Neoplasia (2010) 1.33
Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat (2007) 1.33
Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol (2004) 1.31
A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Lab Invest (2004) 1.31
The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int J Cancer (2009) 1.29
A comparison of feature selection and classification methods in DNA methylation studies using the Illumina Infinium platform. BMC Bioinformatics (2012) 1.26
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26
Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol (2005) 1.22
ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology (2010) 1.20
BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res (2008) 1.20
Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol (2010) 1.18
STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.18
Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer (2011) 1.17
Characterization of adnexal mass lesions on MR imaging. AJR Am J Roentgenol (2003) 1.16
Cellular network entropy as the energy potential in Waddington's differentiation landscape. Sci Rep (2013) 1.12
Using high-density DNA methylation arrays to profile copy number alterations. Genome Biol (2014) 1.11
Mass spectrometric profile of exhaled breath--field study by PTR-MS. Respir Physiol Neurobiol (2005) 1.11
Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins. Proc Natl Acad Sci U S A (2011) 1.11
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med (2013) 1.10
Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain (2005) 1.09
Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS One (2007) 1.08
Pattern of brain atrophy in elderly patients with depression revealed by voxel-based morphometry. Psychiatry Res (2008) 1.08
DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res (2004) 1.06
Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci (2004) 1.06
Methylated DNA as a possible screening marker for neoplastic disease in several body fluids. Expert Rev Mol Diagn (2003) 1.06
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci (2006) 1.06
Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol (2004) 1.06
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res (2005) 1.05
DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer (2009) 1.04
Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. Int J Cancer (2009) 1.02
SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis (2007) 1.02
Common variants in RB1 gene and risk of invasive ovarian cancer. Cancer Res (2006) 1.01
Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res (2010) 1.01
A molecular genetic and statistical approach for the diagnosis of dual-site cancers. J Natl Cancer Inst (2004) 1.00
A Perl toolkit for LIMS development. Source Code Biol Med (2008) 1.00
Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand (2011) 0.99
Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene (2004) 0.99
Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev (2004) 0.99
Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia (2010) 0.99